Check out what some of your colleagues tweeted about during the EAU 2014 Annual Congress.
The 5-year disease-free and cancer-specific survival rates were 94.7% and 100%, respectively.
In a small study, the treatment was associated with a 4-fold increase in average ejaculation time.
Study shows it can provide durable oncologic control with a low risk of tumor recurrence.
Researchers observe benefit in prostate cancer patients with 2 or more adverse pathologic features.
Pelvic lymph node dissection in high-risk patients is 2.5 times more likely in those undergoing open rather than robotic-assisted surgery.
Men with non-palpable tumors had a 46% lower risk of positive surgical margins.
Parenteral testosterone undecanoate over 5 years found to decrease waist circumference and improve components of metabolic syndrome.
Alpha blockers and 5-alpha reductase inhibitors increase the risk of ejaculatory dysfunction, a systematic review and meta-analysis shows.
Risk is not eliminated if patients have risk factors for chronic kidney disease, such as hypertension and diabetes.
Patients are more than 9 times more likely to die from causes other than PCa, a new study shows.
It is associated with a 34.7% decrease in biochemical recurrence after radical prostatectomy versus patients with blood type A.
One year of PSA test results can lead to 10%-20% of men being misclassified as having a high risk of prostate cancer progression.
Modalities under investigation include laser ablation, hemiablative seed implantation, and results are promising.
For patients with metastatic disease receiving systemic treatment, a high BMI was found to improve overall survival.
Biochemical recurrence-free and metastasis-free survival can be achieved.
The trend is due mostly to an increasing incidence of visits by women.
The finding is based on a study of men with low-risk prostate cancer on active surveillance.
Partial or radical nephrectomy improves patients' survival odds, data show.
The trend toward increasing use of percutaneous nephrolithotomy is more pronounced among women than men.
MRI-demonstrated tumors at baseline associated with a higher risk of radiologic progression.